AstraZeneca’s Oncology Strategy Yields Victories
Tagrisso Adjuvant Data, Koselugo NF1 Approval Are Signs Of Progress
The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.
